<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36181767</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2157-6580</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>Stem cells translational medicine</Title><ISOAbbreviation>Stem Cells Transl Med</ISOAbbreviation></Journal><ArticleTitle>Patching Up the Permeability: The Role of Stem Cells in Lessening Neurovascular Damage in Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>1196</StartPage><EndPage>1209</EndPage><MedlinePgn>1196-1209</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/stcltm/szac072</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a debilitating disease with poor prognosis. The pathophysiology of ALS is commonly debated, with theories involving inflammation, glutamate excitotoxity, oxidative stress, mitochondria malfunction, neurofilament accumulation, inadequate nutrients or growth factors, and changes in glial support predominating. These underlying pathological mechanisms, however, act together to weaken the blood brain barrier and blood spinal cord barrier, collectively considered as the blood central nervous system barrier (BCNSB). Altering the impermeability of the BCNSB impairs the neurovascular unit, or interdependent relationship between the brain and advances the concept that ALS is has a significant neurovascular component contributing to its degenerative presentation. This unique categorization of ALS opens a variety of treatment options targeting the reestablishment of BCNSB integrity. This review will critically assess the evidence implicating the significant neurovascular components of ALS pathophysiology, while also offering an in-depth discussion regarding the use of stem cells to repair these pathological changes within the neurovascular unit.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Monsour</LastName><ForeName>Molly</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garbuzova-Davis</LastName><ForeName>Svitlana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of Excellence for Aging and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borlongan</LastName><ForeName>Cesario V</ForeName><Initials>CV</Initials><Identifier Source="ORCID">0000-0002-2966-9782</Identifier><AffiliationInfo><Affiliation>Center of Excellence for Aging and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Stem Cells Transl Med</MedlineTA><NlmUniqueID>101578022</NlmUniqueID><ISSNLinking>2157-6564</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">blood central nervous system barrier</Keyword><Keyword MajorTopicYN="N">neurovascular</Keyword><Keyword MajorTopicYN="N">permeability</Keyword><Keyword MajorTopicYN="N">stem cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>1</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36181767</ArticleId><ArticleId IdType="pmc">PMC9801306</ArticleId><ArticleId IdType="doi">10.1093/stcltm/szac072</ArticleId><ArticleId IdType="pii">6743287</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mills KR. Characteristics of fasciculations in amyotrophic lateral sclerosis and the benign fasciculation syndrome. Brain. 2010;133(11):3458-3469. 10.1093/brain/awq290</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq290</ArticleId><ArticleId IdType="pubmed">20959307</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott EO, Malek AM, Lacomis D.. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol. 2016;138:225-238. 10.1016/B978-0-12-802973-2.00013-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-802973-2.00013-6</ArticleId><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Haverkamp LJ, Appel V, Appel SH.. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118(Pt 3):707-719. 10.1093/brain/118.3.707</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/118.3.707</ArticleId><ArticleId IdType="pubmed">7600088</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland LP, Shneider NA.. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344(22):1688-1700. 10.1056/NEJM200105313442207</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Lyon M, Moore DH.. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 1447;2002(2):CD00.</Citation><ArticleIdList><ArticleId IdType="pubmed">12076411</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS. Edaravone for treatment of early-stage ALS. Lancet Neurol. 2017;16(10):772. 10.1016/S1474-4422(17)30289-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30289-2</ArticleId><ArticleId IdType="pubmed">28920880</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajroud-Driss S, Siddique T.. Sporadic and hereditary amyotrophic lateral sclerosis (ALS). Biochim Biophys Acta. 2015;1852(4):679-684. 10.1016/j.bbadis.2014.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2014.08.010</ArticleId><ArticleId IdType="pubmed">25193032</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Navarro X.. Amyotrophic lateral sclerosis: current perspectives from basic research to the clinic. Prog Neurobiol. 2015;133:1-26. 10.1016/j.pneurobio.2015.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2015.07.004</ArticleId><ArticleId IdType="pubmed">26253783</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Miller TM, Cleveland DW.. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004;27:723-749. 10.1146/annurev.neuro.27.070203.144244</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.27.070203.144244</ArticleId><ArticleId IdType="pubmed">15217349</ArticleId></ArticleIdList></Reference><Reference><Citation>Consilvio C, Vincent AM, Feldman EL.. Neuroinflammation, COX-2, and ALS--a dual role?. Exp Neurol. 2004;187(1):1-10. 10.1016/j.expneurol.2003.12.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.12.009</ArticleId><ArticleId IdType="pubmed">15081582</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Rodrigues MC, Hernandez-Ontiveros DG, et al. . Amyotrophic lateral sclerosis: a neurovascular disease. Brain Res. 2011;1398:113-125. 10.1016/j.brainres.2011.04.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2011.04.049</ArticleId><ArticleId IdType="pubmed">21632035</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P, Brown RH.. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci. 2006;7(9):710-723. 10.1038/nrn1971</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1971</ArticleId><ArticleId IdType="pubmed">16924260</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65(Suppl 1):S3-S9. 10.1002/ana.21543</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21543</ArticleId><ArticleId IdType="pubmed">19191304</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh IA, Zesiewicz T, Xie Y, et al. . Evaluation of humoral immune response in adaptive immunity in ALS patients during disease progression. J Neuroimmunol. 2009;215(1-2):96-101. 10.1016/j.jneuroim.2009.07.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2009.07.011</ArticleId><ArticleId IdType="pubmed">19682755</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Kesavapany S, Pant HC.. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy?. J Neuropathol Exp Neurol. 2005;64(8):649-664. 10.1097/01.jnen.0000173889.71434.ea</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jnen.0000173889.71434.ea</ArticleId><ArticleId IdType="pubmed">16106213</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W.. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2006;1762(11-12):1068-1082. 10.1016/j.bbadis.2006.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.05.002</ArticleId><ArticleId IdType="pubmed">16806844</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirian A, Moszczynski A, Soleimani S, et al. . Breached barriers: a scoping review of blood-central nervous system barrier pathology in amyotrophic lateral sclerosis. Front Cell Neurosci. 2022;16:851563. 10.3389/fncel.2022.851563</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2022.851563</ArticleId><ArticleId IdType="pmc">PMC9009245</ArticleId><ArticleId IdType="pubmed">35431812</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhutani H, Anand A.. Biomarkers in amyotrophic lateral sclerosis: is there a neurovascular pathway?. Curr Neurovasc Res. 2012;9(4):302-309. 10.2174/156720212803530654</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720212803530654</ArticleId><ArticleId IdType="pubmed">22873722</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, Deane R, Ali Z, et al. . ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci. 2008;11(4):420-422. 10.1038/nn2073</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2073</ArticleId><ArticleId IdType="pmc">PMC2895310</ArticleId><ArticleId IdType="pubmed">18344992</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, Yamanaka K, Lobsiger CS, et al. . Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312(5778):1389-1392. 10.1126/science.1123511</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1123511</ArticleId><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Tajti J, Appel SH.. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol. 1993;50(1):30-36. 10.1001/archneur.1993.00540010026013</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1993.00540010026013</ArticleId><ArticleId IdType="pubmed">8093428</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Engelhardt JI, Siklos L, et al. . Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol. 2004;55(2):221-235. 10.1002/ana.10805</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10805</ArticleId><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon MS, Wosiski-Kuhn M, Gillespie R, Caress J, Milligan C.. Inflammation, Immunity, and amyotrophic lateral sclerosis: I. Etiology and pathology. Muscle Nerve. 2019;59(1):10-22. 10.1002/mus.26289</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26289</ArticleId><ArticleId IdType="pubmed">29979464</ArticleId></ArticleIdList></Reference><Reference><Citation>Bataveljic D, Djogo N, Zupunski L, et al. . Live monitoring of brain damage in the rat model of amyotrophic lateral sclerosis. Gen Physiol Biophys. 2009;28 Spec No:212-218.</Citation><ArticleIdList><ArticleId IdType="pubmed">19893103</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson MR, Shaw PJ.. Oxidative stress and motor neurone disease. Brain Pathol. 1999;9(1):165-186. 10.1111/j.1750-3639.1999.tb00217.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.1999.tb00217.x</ArticleId><ArticleId IdType="pmc">PMC8098266</ArticleId><ArticleId IdType="pubmed">9989458</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W. Oxidative stress in amyotrophic lateral sclerosis. J Neurol. 2000;247(Suppl 1):I1-I6. 10.1007/s004150050551</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004150050551</ArticleId><ArticleId IdType="pubmed">10795881</ArticleId></ArticleIdList></Reference><Reference><Citation>Pun PB, Lu J, Moochhala S.. Involvement of ROS in BBB dysfunction. Free Radic Res. 2009;43(4):348-364. 10.1080/10715760902751902</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10715760902751902</ArticleId><ArticleId IdType="pubmed">19241241</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico E, Factor-Litvak P, Santella RM, Mitsumoto H.. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013;65:509-527. 10.1016/j.freeradbiomed.2013.06.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.06.029</ArticleId><ArticleId IdType="pmc">PMC3859834</ArticleId><ArticleId IdType="pubmed">23797033</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y, Karam C, Yi J, et al. . ROS-related mitochondrial dysfunction in skeletal muscle of an ALS mouse model during the disease progression. Pharmacol Res. 2018;138:25-36. 10.1016/j.phrs.2018.09.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2018.09.008</ArticleId><ArticleId IdType="pmc">PMC6263743</ArticleId><ArticleId IdType="pubmed">30236524</ArticleId></ArticleIdList></Reference><Reference><Citation>Armada-Moreira A, Gomes JI, Pina CC, et al. . Going the extra (synaptic) mile: excitotoxicity as the road toward neurodegenerative diseases. Front Cell Neurosci. 2020;14:90. 10.3389/fncel.2020.00090</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.00090</ArticleId><ArticleId IdType="pmc">PMC7194075</ArticleId><ArticleId IdType="pubmed">32390802</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang LL, Zhu B, Zhao Y, et al. . Membralin deficiency dysregulates astrocytic glutamate homeostasis leading to ALS-like impairment. J Clin Invest. 2019;129(8):3103-3120. 10.1172/JCI127695</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI127695</ArticleId><ArticleId IdType="pmc">PMC6668683</ArticleId><ArticleId IdType="pubmed">31112137</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. Neuron 2017;96(1):17-42. 10.1016/j.neuron.2017.07.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.07.030</ArticleId><ArticleId IdType="pmc">PMC5657612</ArticleId><ArticleId IdType="pubmed">28957666</ArticleId></ArticleIdList></Reference><Reference><Citation>Camandola S, Mattson MP.. Brain metabolism in health, aging, and neurodegeneration. EMBO J. 2017;36(11):1474-1492. 10.15252/embj.201695810</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201695810</ArticleId><ArticleId IdType="pmc">PMC5452017</ArticleId><ArticleId IdType="pubmed">28438892</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujioka T, Kaneko N, Sawamoto K.. Blood vessels as a scaffold for neuronal migration. Neurochem Int. 2019;126:69-73. 10.1016/j.neuint.2019.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2019.03.001</ArticleId><ArticleId IdType="pubmed">30851365</ArticleId></ArticleIdList></Reference><Reference><Citation>Malheiro A, Wieringa P, Moroni L.. Peripheral neurovascular link: an overview of interactions and in vitro models. Trends Endocrinol Metab. 2021;32(8):623-638. 10.1016/j.tem.2021.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2021.05.004</ArticleId><ArticleId IdType="pubmed">34127366</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakatsani A, Shah B, Ruiz de Almodovar C.. Blood vessels as regulators of neural stem cell properties. Front Mol Neurosci. 2019;12:85. 10.3389/fnmol.2019.00085</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00085</ArticleId><ArticleId IdType="pmc">PMC6473036</ArticleId><ArticleId IdType="pubmed">31031591</ArticleId></ArticleIdList></Reference><Reference><Citation>Segarra M, Aburto MR, Hefendehl J, Acker-Palmer A.. Neurovascular interactions in the nervous system. Annu Rev Cell Dev Biol. 2019;35:615-635. 10.1146/annurev-cellbio-100818-125142</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-100818-125142</ArticleId><ArticleId IdType="pubmed">31590587</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino S, Polini A, Arima V, et al. . Neurovascular signals in amyotrophic lateral sclerosis. Curr Opin Biotechnol. 2022;74:75-83. 10.1016/j.copbio.2021.10.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.copbio.2021.10.021</ArticleId><ArticleId IdType="pubmed">34800850</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott NJ, Ronnback L, Hansson E.. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7(1):41-53. 10.1038/nrn1824</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1824</ArticleId><ArticleId IdType="pubmed">16371949</ArticleId></ArticleIdList></Reference><Reference><Citation>Prat A, Biernacki K, Wosik K, Antel JP.. Glial cell influence on the human blood-brain barrier. Glia. 2001;36(2):145-155. 10.1002/glia.1104</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.1104</ArticleId><ArticleId IdType="pubmed">11596123</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Flores L, Gutierrez R, Madrid JF, et al. . Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol Histopathol. 2009;24(7):909-969. 10.14670/HH-24.909</Citation><ArticleIdList><ArticleId IdType="doi">10.14670/HH-24.909</ArticleId><ArticleId IdType="pubmed">19475537</ArticleId></ArticleIdList></Reference><Reference><Citation>Kida S, Steart PV, Zhang ET, Weller RO.. Perivascular cells act as scavengers in the cerebral perivascular spaces and remain distinct from pericytes, microglia and macrophages. Acta Neuropathol. 1993;85(6):646-652. 10.1007/BF00334675</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00334675</ArticleId><ArticleId IdType="pubmed">8337943</ArticleId></ArticleIdList></Reference><Reference><Citation>Polfliet MM, Zwijnenburg PJ, van Furth A.M., et al. . Meningeal and perivascular macrophages of the central nervous system play a protective role during bacterial meningitis. J Immunol. 2001;167(8):4644-4650.</Citation><ArticleIdList><ArticleId IdType="pubmed">11591794</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer HC, Bauer H.. Neural induction of the blood-brain barrier: still an enigma. Cell Mol Neurobiol. 2000;20(1):13-28. 10.1023/a:1006939825857</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1006939825857</ArticleId><ArticleId IdType="pubmed">10690499</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradbury MW. The blood-brain barrier. Transport across the cerebral endothelium. Circ Res. 1985;57(2):213-222. 10.1161/01.res.57.2.213</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.res.57.2.213</ArticleId><ArticleId IdType="pubmed">2410161</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin LL, Hall DE, Porter S, et al. . A cell culture model of the blood-brain barrier. J Cell Biol. 1991;115(6):1725-1735. 10.1083/jcb.115.6.1725</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.115.6.1725</ArticleId><ArticleId IdType="pmc">PMC2289219</ArticleId><ArticleId IdType="pubmed">1661734</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernacki J, Dobrowolska A, Nierwinska K, Malecki A.. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep. 2008;60(5):600-622.</Citation><ArticleIdList><ArticleId IdType="pubmed">19066407</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolburg H, Noell S, Mack A, Wolburg-Buchholz K, Fallier-Becker P.. Brain endothelial cells and the glio-vascular complex. Cell Tissue Res. 2009;335(1):75-96. 10.1007/s00441-008-0658-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-008-0658-9</ArticleId><ArticleId IdType="pubmed">18633647</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddahi A, Edvinsson L.. Enhanced expressions of microvascular smooth muscle receptors after focal cerebral ischemia occur via the MAPK MEK/ERK pathway. BMC Neurosci. 2008;9:85. 10.1186/1471-2202-9-85</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-9-85</ArticleId><ArticleId IdType="pmc">PMC2553085</ArticleId><ArticleId IdType="pubmed">18793415</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis CA, Solomon JN, Rossi FM, Krieger C.. Bone marrow-derived cells in the central nervous system of a mouse model of amyotrophic lateral sclerosis are associated with blood vessels and express CX(3)CR1. Glia 2009;57(13):1410-1419. 10.1002/glia.20859</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20859</ArticleId><ArticleId IdType="pubmed">19243075</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Siddiqui S, Gabriely G, et al. . Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest. 2012;122(9):3063-3087. 10.1172/JCI62636</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI62636</ArticleId><ArticleId IdType="pmc">PMC3428086</ArticleId><ArticleId IdType="pubmed">22863620</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttenplan KA, Weigel MK, Adler DI, et al. . Knockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model. Nat Commun. 2020;11(1):3753. 10.1038/s41467-020-17514-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17514-9</ArticleId><ArticleId IdType="pmc">PMC7385161</ArticleId><ArticleId IdType="pubmed">32719333</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, et al. . Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481-487. 10.1038/nature21029</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giovanni S, Movsesyan V, Ahmed F, et al. . Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc Natl Acad Sci USA. 2005;102(23):8333-8338. 10.1073/pnas.0500989102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0500989102</ArticleId><ArticleId IdType="pmc">PMC1149422</ArticleId><ArticleId IdType="pubmed">15923260</ArticleId></ArticleIdList></Reference><Reference><Citation>Meister S, Storck SE, Hameister E, et al. . Expression of the ALS-causing variant hSOD1(G93A) leads to an impaired integrity and altered regulation of claudin-5 expression in an in vitro blood-spinal cord barrier model. J Cereb Blood Flow Metab. 2015;35(7):1112-1121. 10.1038/jcbfm.2015.57</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2015.57</ArticleId><ArticleId IdType="pmc">PMC4640277</ArticleId><ArticleId IdType="pubmed">25853911</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Saporta S, Sanberg PR.. Implications of blood-brain barrier disruption in ALS. Amyotroph Lateral Scler. 2008;9(6):375-376. 10.1080/17482960802160990</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802160990</ArticleId><ArticleId IdType="pubmed">18608097</ArticleId></ArticleIdList></Reference><Reference><Citation>Boswell CA, Mundo EE, Johnstone B, et al. . Vascular physiology and protein disposition in a preclinical model of neurodegeneration. Mol Pharm. 2013;10(5):1514-1521. 10.1021/mp3004786</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/mp3004786</ArticleId><ArticleId IdType="pubmed">23383983</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Saporta S, Haller E, et al. . Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS One. 2007;2(11):e1205. 10.1371/journal.pone.0001205</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001205</ArticleId><ArticleId IdType="pmc">PMC2075163</ArticleId><ArticleId IdType="pubmed">18030339</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Haller E, Saporta S, et al. . Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 2007;1157:126-137. 10.1016/j.brainres.2007.04.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.04.044</ArticleId><ArticleId IdType="pubmed">17512910</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicaise C, Soyfoo MS, Authelet M, et al. . Aquaporin-4 overexpression in rat ALS model. Anat Rec (Hoboken). 2009;292(2):207-213. 10.1002/ar.20838</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ar.20838</ArticleId><ArticleId IdType="pubmed">19089902</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe-Matsumoto S, Moriwaki Y, Okuda T, et al. . Dissociation of blood-brain barrier disruption and disease manifestation in an aquaporin-4-deficient mouse model of amyotrophic lateral sclerosis. Neurosci Res. 2018;133:48-57. 10.1016/j.neures.2017.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2017.11.001</ArticleId><ArticleId IdType="pubmed">29154923</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki K, Ohta Y, Nagai M, et al. . Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J Neurosci Res. 2011;89(5):718-728. 10.1002/jnr.22594</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22594</ArticleId><ArticleId IdType="pubmed">21337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshikawa M, Aizawa S, Oppenheim RW, Milligan C.. Neurovascular unit pathology is observed very early in disease progression in the mutant SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2022;353:114084. 10.1016/j.expneurol.2022.114084</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2022.114084</ArticleId><ArticleId IdType="pubmed">35439439</ArticleId></ArticleIdList></Reference><Reference><Citation>Haseloff RF, Blasig IE, Bauer HC, Bauer H.. In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro. Cell Mol Neurobiol. 2005;25(1):25-39. 10.1007/s10571-004-1375-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-004-1375-x</ArticleId><ArticleId IdType="pubmed">15962507</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa S, Deli MA, Nakao S, et al. . Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell Mol Neurobiol. 2007;27(6):687-694. 10.1007/s10571-007-9195-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-007-9195-4</ArticleId><ArticleId IdType="pubmed">17823866</ArticleId></ArticleIdList></Reference><Reference><Citation>Tontsch U, Bauer HC.. Glial cells and neurons induce blood-brain barrier related enzymes in cultured cerebral endothelial cells. Brain Res. 1991;539(2):247-253. 10.1016/0006-8993(91)91628-e</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(91)91628-e</ArticleId><ArticleId IdType="pubmed">1675906</ArticleId></ArticleIdList></Reference><Reference><Citation>Correction: transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and phase 2 trials. Neurology 2017;89(5):521.</Citation><ArticleIdList><ArticleId IdType="pubmed">28760918</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishioku T, Matsumoto J, Dohgu S, et al. . Tumor necrosis factor-alpha mediates the blood-brain barrier dysfunction induced by activated microglia in mouse brain microvascular endothelial cells. J Pharmacol Sci. 2010;112(2):251-254.</Citation><ArticleIdList><ArticleId IdType="pubmed">20118615</ArticleId></ArticleIdList></Reference><Reference><Citation>Candelario-Jalil E, Yang Y, Rosenberg GA.. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience. 2009;158(3):983-994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3584171</ArticleId><ArticleId IdType="pubmed">18621108</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda S, Fini CA, Mabuchi T, et al. . Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke. 2004;35(4):998-1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2979008</ArticleId><ArticleId IdType="pubmed">15001799</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia. 2002;39(3):279-291.</Citation><ArticleIdList><ArticleId IdType="pubmed">12203394</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang L, Teuchert M, Huber-Abel F, et al. . MMP-2 and MMP-9 are elevated in spinal cord and skin in a mouse model of ALS. J Neurol Sci. 2010;294(1-2):51-56.</Citation><ArticleIdList><ArticleId IdType="pubmed">20441996</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronaldson PT, Demarco KM, Sanchez-Covarrubias L, Solinsky CM, Davis TP.. Transforming growth factor-beta signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during inflammatory pain. J Cereb Blood Flow Metab. 2009;29(6):1084-1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3910515</ArticleId><ArticleId IdType="pubmed">19319146</ArticleId></ArticleIdList></Reference><Reference><Citation>Galbiati M, Crippa V, Rusmini P, et al. . , Multiple roles of transforming growth factor beta in amyotrophic lateral sclerosis. Int J Mol Sci . 2020;21(12):1-17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7352289</ArticleId><ArticleId IdType="pubmed">32560258</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Henderson RD.. The role of immune and inflammatory mechanisms in ALS. Curr Mol Med. 2011;11(3):246-254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3182412</ArticleId><ArticleId IdType="pubmed">21375489</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamudio F, Loon AR, Smeltzer S, et al. . TDP-43 mediated blood-brain barrier permeability and leukocyte infiltration promote neurodegeneration in a low-grade systemic inflammation mouse model. J Neuroinflammation. 2020;17(1):283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7519496</ArticleId><ArticleId IdType="pubmed">32979923</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, Iguchi Y, Katsuno M, Sobue G.. Alterations in the blood-spinal cord barrier in TDP-43 conditional knockout mice. Neurosci Lett. 2015;598:1-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">25957558</ArticleId></ArticleIdList></Reference><Reference><Citation>Waters S, Swanson MEV, Dieriks BV, et al. . Blood-spinal cord barrier leakage is independent of motor neuron pathology in ALS. Acta Neuropathol Commun. 2021;9(1):144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8393479</ArticleId><ArticleId IdType="pubmed">34446086</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A, Thakur K, Gupta PK.. ALS and oxidative stress: the neurovascular scenario. Oxid Med Cell Longev. 2013;2013:635831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3866720</ArticleId><ArticleId IdType="pubmed">24367722</ArticleId></ArticleIdList></Reference><Reference><Citation>Qosa H, Lichter J, Sarlo M, et al. . Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P-Glycoprotein) in endothelial cells of the blood-brain barrier in mutant superoxide dismutase 1-linked amyotrophic lateral sclerosis. Glia. 2016;64(8):1298-1313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5541958</ArticleId><ArticleId IdType="pubmed">27158936</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamenkovic S, Pavicevic A, Mojovic M, et al. . In vivo EPR pharmacokinetic evaluation of the redox status and the blood brain barrier permeability in the SOD1(G93A) ALS rat model. Free Radic Biol Med. 2017;108:258-269.</Citation><ArticleIdList><ArticleId IdType="pubmed">28366802</ArticleId></ArticleIdList></Reference><Reference><Citation>Huai J, Zhang Z.. Structural properties and interaction partners of familial ALS-associated SOD1 mutants. Front Neurol. 2019;10:527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536575</ArticleId><ArticleId IdType="pubmed">31164862</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossini E, Garhwal D, Venkatesan S, et al. . , The potential role of peripheral oxidative stress on the neurovascular unit in amyotrophic lateral sclerosis pathogenesis: a preliminary report from human and in vitro evaluations. Biomedicines. 2022;10(3):1-14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8945260</ArticleId><ArticleId IdType="pubmed">35327493</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J, Kang Y, Zhou Y, et al. . ALS-causing SOD1 mutants regulate occludin phosphorylation/ubiquitination and endocytic trafficking via the ITCH/Eps15/Rab5 axis. Neurobiol Dis. 2021;153:105315.</Citation><ArticleIdList><ArticleId IdType="pubmed">33636390</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sengillo JD, Sagare AP, et al. . Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci USA. 2014;111(11):E1035-E1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964055</ArticleId><ArticleId IdType="pubmed">24591593</ArticleId></ArticleIdList></Reference><Reference><Citation>Rule RR, Schuff N, Miller RG, Weiner MW.. Gray matter perfusion correlates with disease severity in ALS. Neurology. 2010;74(10):821-827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839193</ArticleId><ArticleId IdType="pubmed">20147656</ArticleId></ArticleIdList></Reference><Reference><Citation>Arhart RW. A possible haemodynamic mechanism for amyotrophic lateral sclerosis. Med Hypotheses. 2010;75(4):341-346.</Citation><ArticleIdList><ArticleId IdType="pubmed">20400230</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranno E, D&#x2019;Antoni S, Spatuzza M, et al. . Endothelin-1 is over-expressed in amyotrophic lateral sclerosis and induces motor neuron cell death. Neurobiol Dis. 2014;65:160-171.</Citation><ArticleIdList><ArticleId IdType="pubmed">24423643</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrenovitch TP. Amyotrophic lateral sclerosis, excitotoxicity and riluzole. Trends Pharmacol Sci. 1998;19(1):9-11.</Citation><ArticleIdList><ArticleId IdType="pubmed">9509893</ArticleId></ArticleIdList></Reference><Reference><Citation>Argaw AT, Asp L, Zhang J, et al. . Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest. 2012;122(7):2454-2468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3386814</ArticleId><ArticleId IdType="pubmed">22653056</ArticleId></ArticleIdList></Reference><Reference><Citation>Esser S, Lampugnani MG, Corada M, Dejana E, Risau W.. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci. 1998;111(Pt 13):1853-1865.</Citation><ArticleIdList><ArticleId IdType="pubmed">9625748</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins RA. The blood-brain barrier and glutamate. Am J Clin Nutr. 2009;90(3):867S-874S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136011</ArticleId><ArticleId IdType="pubmed">19571220</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblum LT, Shamamandri-Markandaiah S, Ghosh B, et al. . Mutation of the caspase-3 cleavage site in the astroglial glutamate transporter EAAT2 delays disease progression and extends lifespan in the SOD1-G93A mouse model of ALS. Exp Neurol. 2017;292:145-153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5433801</ArticleId><ArticleId IdType="pubmed">28342750</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu XD, Liu GQ.. P glycoprotein regulated transport of glutamate at blood brain barrier. Acta Pharmacol Sin. 2001;22(2):111-116.</Citation><ArticleIdList><ArticleId IdType="pubmed">11741514</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed LA, Markandaiah SS, Bonanno S, Pasinelli P, Trotti D.. Excess glutamate secreted from astrocytes drives upregulation of P-glycoprotein in endothelial cells in amyotrophic lateral sclerosis. Exp Neurol. 2019;316:27-38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6506236</ArticleId><ArticleId IdType="pubmed">30974102</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vliet EA, Iyer AM, Mesarosova L, et al. . Expression and cellular distribution of P-glycoprotein and breast cancer resistance protein in amyotrophic lateral sclerosis patients. J Neuropathol Exp Neurol. 2020;79(3):266-276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7036662</ArticleId><ArticleId IdType="pubmed">31999342</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecuyer MA, Kebir H, Prat A.. Glial influences on BBB functions and molecular players in immune cell trafficking. Biochim Biophys Acta. 2016;1862(3):472-482.</Citation><ArticleIdList><ArticleId IdType="pubmed">26454208</ArticleId></ArticleIdList></Reference><Reference><Citation>Begani Provinciali G, Pieroni N, Bukreeva I, et al. . X-ray phase contrast tomography for the investigation of amyotrophic lateral sclerosis. J Synchrotron Radiat. 2020;27(Pt 4):1042-1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7336179</ArticleId><ArticleId IdType="pubmed">33566014</ArticleId></ArticleIdList></Reference><Reference><Citation>Andjus PR, Bataveljic D, Vanhoutte G, et al. . In vivo morphological changes in animal models of amyotrophic lateral sclerosis and Alzheimer&#x2019;s-like disease: MRI approach. Anat Rec (Hoboken). 2009;292(12):1882-1892.</Citation><ArticleIdList><ArticleId IdType="pubmed">19943341</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans MC, Serres S, Khrapitchev AA, et al. . T(2)-weighted MRI detects presymptomatic pathology in the SOD1 mouse model of ALS. J Cereb Blood Flow Metab. 2014;34(5):785-793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4013759</ArticleId><ArticleId IdType="pubmed">24496176</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnenfeld H, Kascsak RJ, Bartfeld H.. Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J Neuroimmunol. 1984;6(1):51-57.</Citation><ArticleIdList><ArticleId IdType="pubmed">6368581</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Appel SH.. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol. 1990;47(11):1210-1216.</Citation><ArticleIdList><ArticleId IdType="pubmed">2122877</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Siklos L, Komuves L, Smith RG, Appel SH.. Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motoneurons. Synapse. 1995;20(3):185-199.</Citation><ArticleIdList><ArticleId IdType="pubmed">7570350</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonardi A, Abbruzzese G, Arata L, Cocito L, Vische M.. Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis. J Neurol. 1984;231(2):75-78.</Citation><ArticleIdList><ArticleId IdType="pubmed">6737012</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Hernandez-Ontiveros DG, Rodrigues MC, et al. . Impaired blood-brain/spinal cord barrier in ALS patients. Brain Res. 2012;1469:114-128.</Citation><ArticleIdList><ArticleId IdType="pubmed">22750125</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sengillo JD, Sullivan JS, et al. . Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125(1):111-120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535352</ArticleId><ArticleId IdType="pubmed">22941226</ArticleId></ArticleIdList></Reference><Reference><Citation>Armulik A, Genove G, Betsholtz C.. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011;21(2):193-215.</Citation><ArticleIdList><ArticleId IdType="pubmed">21839917</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, Bowser R, Appel SH.. Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology. 2009;72(18):1614-1616.</Citation><ArticleIdList><ArticleId IdType="pubmed">19414730</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono S, Imai T, Takahashi K, et al. . Decreased type IV collagen of skin and serum in patients with amyotrophic lateral sclerosis. Neurology. 1998;51(1):114-120.</Citation><ArticleIdList><ArticleId IdType="pubmed">9674788</ArticleId></ArticleIdList></Reference><Reference><Citation>Beuche W, Yushchenko M, Mader M, et al. . Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport. 2000;11(16):3419-3422.</Citation><ArticleIdList><ArticleId IdType="pubmed">11095490</ArticleId></ArticleIdList></Reference><Reference><Citation>Demestre M, Parkin-Smith G, Petzold A, Pullen AH.. The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. J Neuroimmunol. 2005;159(1-2):146-154.</Citation><ArticleIdList><ArticleId IdType="pubmed">15652414</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim GP, Backstrom JR, Cullen MJ, et al. . Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. J Neurochem. 1996;67(1):251-259.</Citation><ArticleIdList><ArticleId IdType="pubmed">8666998</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossolasco P, Cova L, Calzarossa C, et al. . Metalloproteinase alterations in the bone marrow of ALS patients. J Mol Med (Berl). 2010;88(6):553-564.</Citation><ArticleIdList><ArticleId IdType="pubmed">20091292</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy MJ, Grace GM, Tartaglia MC, et al. . Widespread cerebral haemodynamics disturbances occur early in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13(2):202-209.</Citation><ArticleIdList><ArticleId IdType="pubmed">22292841</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S. Alterations of the blood-spinal cord barrier in sporadic amyotrophic lateral sclerosis. Neuropathology. 2015;35(6):518-528.</Citation><ArticleIdList><ArticleId IdType="pubmed">26242689</ArticleId></ArticleIdList></Reference><Reference><Citation>Manberg A, Skene N, Sanders F, et al. . Altered perivascular fibroblast activity precedes ALS disease onset. Nat Med. 2021;27(4):640-646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7613336</ArticleId><ArticleId IdType="pubmed">33859435</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadrzadeh SM, Graf E, Panter SS, Hallaway PE, Eaton JW.. Hemoglobin. A biologic fenton reagent. J Biol Chem. 1984;259(23):14354-14356.</Citation><ArticleIdList><ArticleId IdType="pubmed">6094553</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwan JY, Jeong SY, Van Gelderen P, et al. . Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology. PLoS One. 2012;7(4):e35241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3328441</ArticleId><ArticleId IdType="pubmed">22529995</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindvall O, Kokaia Z.. Stem cells for the treatment of neurological disorders. Nature. 2006;441(7097):1094-1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">16810245</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera LC, Leigh PN.. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal S, Cudkowicz M.. ALS drug development: reflections from the past and a way forward. Neurotherapeutics. 2008;5(4):516-527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4514695</ArticleId><ArticleId IdType="pubmed">19019302</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella S, Santamato A, Lamberti P.. Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiatr Dis Treat. 2009;5:577-595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785861</ArticleId><ArticleId IdType="pubmed">19966906</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanes C, Bonilla S, Tabares L, Martinez S.. Neuroprotective effect of adult hematopoietic stem cells in a mouse model of motoneuron degeneration. Neurobiol Dis. 2007;26(2):408-418.</Citation><ArticleIdList><ArticleId IdType="pubmed">17337196</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Yan J, Chen D, et al. . Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation. 2006;82(7):865-875.</Citation><ArticleIdList><ArticleId IdType="pubmed">17038899</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiaffino L, Bonafede R, Scambi I, et al. . Acetylation state of RelA modulated by epigenetic drugs prolongs survival and induces a neuroprotective effect on ALS murine model. Sci Rep. 2018;8(1):12875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6110772</ArticleId><ArticleId IdType="pubmed">30150770</ArticleId></ArticleIdList></Reference><Reference><Citation>Shruthi S, Sumitha R, Varghese AM, et al. . Brain-derived neurotrophic factor facilitates functional recovery from ALS-cerebral spinal fluid-induced neurodegenerative changes in the NSC-34 motor neuron cell line. Neurodegener Dis. 2017;17(1):44-58.</Citation><ArticleIdList><ArticleId IdType="pubmed">27617773</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan J, Xu L, Welsh AM, et al. . Extensive neuronal differentiation of human neural stem cell grafts in adult rat spinal cord. PLoS Med. 2007;4(2):e39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796906</ArticleId><ArticleId IdType="pubmed">17298165</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadon-Nachum M, Ben-Yaacov K, Ben-Zur T, et al. . Transplanted modified muscle progenitor cells expressing a mixture of neurotrophic factors delay disease onset and enhance survival in the SOD1 mouse model of ALS. J Mol Neurosci. 2015;55(3):788-797.</Citation><ArticleIdList><ArticleId IdType="pubmed">25330859</ArticleId></ArticleIdList></Reference><Reference><Citation>Krakora D, Mulcrone P, Meyer M, et al. . Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model. Mol Ther. 2013;21(8):1602-1610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3734670</ArticleId><ArticleId IdType="pubmed">23712039</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M, McHugh J, Tork C, et al. . Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol Ther. 2008;16(12):2002-2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678899</ArticleId><ArticleId IdType="pubmed">18797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M, McHugh J, Tork C, et al. . GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One. 2007;2(8):e689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1925150</ArticleId><ArticleId IdType="pubmed">17668067</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, Kim HT, Yun S, et al. . Growth factor-expressing human neural progenitor cell grafts protect motor neurons but do not ameliorate motor performance and survival in ALS mice. Exp Mol Med. 2009;41(7):487-500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2721146</ArticleId><ArticleId IdType="pubmed">19322031</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovich-Nikitin I, Ezra A, Barbiro B, Rabinovich-Toidman P, Solomon B.. Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1(G93A) mice model of ALS. J Neuroinflammation. 2016;13(1):123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4882847</ArticleId><ArticleId IdType="pubmed">27230771</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Haller E, Navarro S, et al. . Transplantation of human bone marrow stem cells into symptomatic ALS mice enhances structural and functional blood-spinal cord barrier repair. Exp Neurol. 2018;310:33-47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6203661</ArticleId><ArticleId IdType="pubmed">30172620</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Kurien C, Thomson A, et al. . Endothelial and astrocytic support by human bone marrow stem cell grafts into symptomatic ALS mice towards blood-spinal cord barrier repair. Sci Rep. 2017;7(1):884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5429840</ArticleId><ArticleId IdType="pubmed">28408761</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Woods RL 3rd, Louis MK, et al. . Reduction of circulating endothelial cells in peripheral blood of ALS patients. PLoS One. 2010;5(5):e10614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868893</ArticleId><ArticleId IdType="pubmed">20485543</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Ehrhart J, Mustafa H, et al. . Phenotypic characteristics of human bone marrow-derived endothelial progenitor cells in vitro support cell effectiveness for repair of the blood-spinal cord barrier in ALS. Brain Res. 2019;1724:146428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6779528</ArticleId><ArticleId IdType="pubmed">31493389</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Kurien C, Haller E, et al. . Human bone marrow endothelial progenitor cell transplantation into symptomatic ALS mice delays disease progression and increases motor neuron survival by repairing blood-spinal cord barrier. Sci Rep. 2019;9(1):5280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6437219</ArticleId><ArticleId IdType="pubmed">30918315</ArticleId></ArticleIdList></Reference><Reference><Citation>Master Z, McLeod M, Mendez I.. Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson&#x2019;s disease. J Med Ethics. 2007;33(3):169-173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2598267</ArticleId><ArticleId IdType="pubmed">17329391</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Savelieff MG, Sakowski SA, Feldman EL.. Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials. Expert Opin Investig Drugs. 2019;28(6):525-543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697143</ArticleId><ArticleId IdType="pubmed">31189354</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Ende N.. The potential for the use of mononuclear cells from human umbilical cord blood in the treatment of amyotrophic lateral sclerosis in SOD1 mice. J Med. 2000;31(1-2):21-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10998753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ende N, Weinstein F, Chen R, Ende M.. Human umbilical cord blood effect on sod mice (amyotrophic lateral sclerosis). Life Sci. 2000;67(1):53-59.</Citation><ArticleIdList><ArticleId IdType="pubmed">10896029</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Willing AE, Zigova T, et al. . Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation. J Hematother Stem Cell Res. 2003;12(3):255-270.</Citation><ArticleIdList><ArticleId IdType="pubmed">12857367</ArticleId></ArticleIdList></Reference><Reference><Citation>Anthony S, Cabantan D, Monsour M, Borlongan CV.. Neuroinflammation, stem cells, and stroke. Stroke 2022;53(5):1460-1472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9038685</ArticleId><ArticleId IdType="pubmed">35380050</ArticleId></ArticleIdList></Reference><Reference><Citation>Uccelli A, Milanese M, Principato MC, et al. . Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis. Mol Med. 2012;18:794-804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409288</ArticleId><ArticleId IdType="pubmed">22481270</ArticleId></ArticleIdList></Reference><Reference><Citation>Marconi S, Bonaconsa M, Scambi I, et al. . Systemic treatment with adipose-derived mesenchymal stem cells ameliorates clinical and pathological features in the amyotrophic lateral sclerosis murine model. Neuroscience 2013;248:333-343.</Citation><ArticleIdList><ArticleId IdType="pubmed">23727509</ArticleId></ArticleIdList></Reference><Reference><Citation>Terashima T, Kobashi S, Watanabe Y, et al. . Enhancing the therapeutic efficacy of bone marrow-derived mononuclear cells with growth factor-expressing mesenchymal stem cells for ALS in mice. iScience 2020;23(11):101764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7677706</ArticleId><ArticleId IdType="pubmed">33251493</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang BL. The use of mesenchymal stem cells (MSCs) for amyotrophic lateral sclerosis (ALS) therapy - a perspective on cell biological mechanisms. Rev Neurosci. 2017;28(7):725-738.</Citation><ArticleIdList><ArticleId IdType="pubmed">28599400</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegyi B, Kornyei Z, Ferenczi S, et al. . Regulation of mouse microglia activation and effector functions by bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 2014;23(21):2600-2612.</Citation><ArticleIdList><ArticleId IdType="pubmed">24870815</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan K, Zhang R, Sun C, et al. . Bone marrow-derived mesenchymal stem cells maintain the resting phenotype of microglia and inhibit microglial activation. PLoS One. 2013;8(12):e84116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877190</ArticleId><ArticleId IdType="pubmed">24391898</ArticleId></ArticleIdList></Reference><Reference><Citation>Uccelli A, Laroni A, Freedman MS.. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol. 2011;10(7):649-656.</Citation><ArticleIdList><ArticleId IdType="pubmed">21683930</ArticleId></ArticleIdList></Reference><Reference><Citation>Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell 2012;10(6):709-716.</Citation><ArticleIdList><ArticleId IdType="pubmed">22704511</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Appel SH.. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol. 2013;8(4):888-899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. . Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010;67(10):1187-1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3036569</ArticleId><ArticleId IdType="pubmed">20937945</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi SM, Arab L, Jarooghi N, et al. . Safety, feasibility of intravenous and intrathecal injection of autologous bone marrow derived mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: an open label phase I clinical trial. Cell J. 2019;20(4):592-598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6099146</ArticleId><ArticleId IdType="pubmed">30124008</ArticleId></ArticleIdList></Reference><Reference><Citation>Noh MY, Lim SM, Oh KW, et al. . Mesenchymal stem cells modulate the functional properties of microglia via TGF-beta secretion. Stem Cells Transl Med. 2016;5(11):1538-1549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070497</ArticleId><ArticleId IdType="pubmed">27400795</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustenhoven J, Aalderink M, Scotter EL, et al. . TGF-beta1 regulates human brain pericyte inflammatory processes involved in neurovasculature function. J Neuroinflammation. 2016;13:37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4751726</ArticleId><ArticleId IdType="pubmed">26867675</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawaguchi-Niida M, Yamamoto T, Kato Y, Inose Y, Shibata N.. MCP-1/CCR2 signaling-mediated astrocytosis is accelerated in a transgenic mouse model of SOD1-mutated familial ALS. Acta Neuropathol Commun. 2013;1:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893446</ArticleId><ArticleId IdType="pubmed">24252211</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman EL, Boulis NM, Hur J, et al. . Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol. 2014;75(3):363-373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4005820</ArticleId><ArticleId IdType="pubmed">24510776</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Ferrero I, Luparello V, et al. . Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial. Exp Neurol. 2010;223(1):229-237.</Citation><ArticleIdList><ArticleId IdType="pubmed">19682989</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Mareschi K, Ferrero I, et al. . Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. Cytotherapy. 2012;14(1):56-60.</Citation><ArticleIdList><ArticleId IdType="pubmed">21954839</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass JD, Boulis NM, Johe K, et al. . Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells. 2012;30(6):1144-1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">22415942</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass JD, Hertzberg VS, Boulis NM, et al. . Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials. Neurology. 2016;87(4):392-400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4977116</ArticleId><ArticleId IdType="pubmed">27358335</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadon-Nachum M, Melamed E, Offen D.. The &#x201c;dying-back&#x201d; phenomenon of motor neurons in ALS. J Mol Neurosci. 2011;43(3):470-477.</Citation><ArticleIdList><ArticleId IdType="pubmed">21057983</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrou P, Gothelf Y, Argov Z, et al. . Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol. 2016;73(3):337-344.</Citation><ArticleIdList><ArticleId IdType="pubmed">26751635</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Armon C.. Stem cells in amyotrophic lateral sclerosis: ready for prime time?. Neurology. 2016;87(4):348-349.</Citation><ArticleIdList><ArticleId IdType="pubmed">27358334</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Cudkowicz ME, Windebank AJ, et al. . NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. Neurology. 2019;93(24):e2294-e2305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6937497</ArticleId><ArticleId IdType="pubmed">31740545</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B, Zhang Y, Du XF, et al. . Neurons secrete miR-132-containing exosomes to regulate brain vascular integrity. Cell Res. 2017;27(7):882-897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5518987</ArticleId><ArticleId IdType="pubmed">28429770</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi C, Napoli G, Amadio S, et al. . MicroRNA-125b regulates microglia activation and motor neuron death in ALS. Cell Death Differ. 2016;23(3):531-541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5072447</ArticleId><ArticleId IdType="pubmed">26794445</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi C, Napoli G, Pelegrin P, Volonte C.. M1 and M2 functional imprinting of primary microglia: role of P2X7 activation and miR-125b. Mediators Inflamm. 2016;2016:2989548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5206439</ArticleId><ArticleId IdType="pubmed">28090150</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanquer M, Moraleda JM, Iniesta F, et al. . Neurotrophic bone marrow cellular nests prevent spinal motoneuron degeneration in amyotrophic lateral sclerosis patients: a pilot safety study. Stem Cells. 2012;30(6):1277-1285.</Citation><ArticleIdList><ArticleId IdType="pubmed">22415951</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouali Alami N, Tang L, Wiesner D, et al. . , Multiplexed chemogenetics in astrocytes and motoneurons restore blood-spinal cord barrier in ALS. Life Sci Alliance. 2020;3(11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7479971</ArticleId><ArticleId IdType="pubmed">32900826</ArticleId></ArticleIdList></Reference><Reference><Citation>Artus C, Glacial F, Ganeshamoorthy K, et al. . The Wnt/planar cell polarity signaling pathway contributes to the integrity of tight junctions in brain endothelial cells. J Cereb Blood Flow Metab. 2014;34(3):433-440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3948118</ArticleId><ArticleId IdType="pubmed">24346691</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebner S, Corada M, Bangsow T, et al. . Wnt/beta-catenin signaling controls development of the blood-brain barrier. J Cell Biol. 2008;183(3):409-417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575783</ArticleId><ArticleId IdType="pubmed">18955553</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenman JM, Rajagopal J, Carroll TJ, et al. . Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature. Science. 2008;322(5905):1247-1250.</Citation><ArticleIdList><ArticleId IdType="pubmed">19023080</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh KW, Noh MY, Kwon MS, et al. . Repeated intrathecal mesenchymal stem cells for amyotrophic lateral sclerosis. Ann Neurol. 2018;84(3):361-373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6175096</ArticleId><ArticleId IdType="pubmed">30048006</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrou P, Kassis I, Yaghmour NE, Ginzberg A, Karussis D.. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis. Front Biosci (Landmark Ed). 2021;26(10):693-706.</Citation><ArticleIdList><ArticleId IdType="pubmed">34719198</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Shen P, Hazel T, Johe K, Koliatsos VE.. Dual transplantation of human neural stem cells into cervical and lumbar cord ameliorates motor neuron disease in SOD1 transgenic rats. Neurosci Lett. 2011;494(3):222-226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098614</ArticleId><ArticleId IdType="pubmed">21402124</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>